Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Prediction Of Disease-free Survival By The PET/CT Radiomic Signature In Non-small Cell Lung Cancer Patients Undergoing Surgery

M. Kirienko, L. Cozzi, L. Antunovic, Lisa Lozza, A. Fogliata, E. Voulaz, A. Rossi, A. Chiti, M. Sollini
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PurposeRadiomic features derived from the texture analysis of different imaging modalities e show promise in lesion characterisation, response prediction, and prognostication in lung cancer patients. The present study aimed to identify an images-based radiomic signature capable of predicting disease-free survival (DFS) in non-small cell lung cancer (NSCLC) patients undergoing surgery.MethodsA cohort of 295 patients was selected. Clinical parameters (age, sex, histological type, tumour grade, and stage) were recorded for all patients. The endpoint of this study was DFS. Both computed tomography (CT) and fluorodeoxyglucose positron emission tomography (PET) images generated from the PET/CT scanner were analysed. Textural features were calculated using the LifeX package. Statistical analysis was performed using the R platform. The datasets were separated into two cohorts by random selection to perform training and validation of the statistical models. Predictors were fed into a multivariate Cox proportional hazard regression model and the receiver operating characteristic (ROC) curve as well as the corresponding area under the curve (AUC) were computed for each model built.ResultsThe Cox models that included radiomic features for the CT, the PET, and the PET+CT images resulted in an AUC of 0.75 (95%CI: 0.65–0.85), 0.68 (95%CI: 0.57–0.80), and 0.68 (95%CI: 0.58–0.74), respectively. The addition of clinical predictors to the Cox models resulted in an AUC of 0.61 (95%CI: 0.51–0.69), 0.64 (95%CI: 0.53–0.75), and 0.65 (95%CI: 0.50–0.72) for the CT, the PET, and the PET+CT images, respectively.ConclusionsA radiomic signature, for either CT, PET, or PET/CT images, has been identified and validated for the prediction of disease-free survival in patients with non-small cell lung cancer treated by surgery.
This paper references
10.1007/s00259-016-3325-5
Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III
Marie-Charlotte Desseroit (2016)
10.1371/journal.pone.0124165
False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review
A. Chalkidou (2015)
10.1016/j.radonc.2015.02.015
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma.
T. Coroller (2015)
10.1007/s00330-017-4855-3
Comparison of a radiomic biomarker with volumetric analysis for decoding tumour phenotypes of lung adenocarcinoma with different disease-specific survival
Mei Yuan (2017)
10.1007/s00259-014-2961-x
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
R. Boellaard (2014)
10.1038/ncomms5006
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
H. Aerts (2014)
10.1038/srep11044
Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer
Chintan Parmar (2015)
The revised TNM staging system for lung cancer.
R. Rami-Porta (2009)
10.1164/RCCM.200706-815OC
Survival after surgery in stage IA and IB non-small cell lung cancer.
D. Ost (2008)
FDGPET/CT: EANMprocedure guidelines for tumour imaging: version 2.0
R Boellaard (2014)
10.4065/83.5.584
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
J. Molina (2008)
10.3978/j.issn.2218-6751.2013.12.05
Recurrence after surgery in patients with NSCLC.
H. Uramoto (2014)
10.1093/annonc/mdu089
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
J. Vansteenkiste (2014)
Technical Appendix — Local Image Features Extraction— — LIFEx
F Orlhac (2016)
10.1371/journal.pone.0123853
Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development
Benjarin Santatiwongchai (2015)
10.1038/s41598-017-00426-y
PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology
M. Sollini (2017)
10.1016/0301-679x(78)90071-3
A decade of progress.
L. Leslie (1969)
10.1016/j.radonc.2017.04.016
Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images.
J. E. van Timmeren (2017)
10.1080/23808993.2016.1164013
Radiomics: a new application from established techniques
V. Parekh (2016)
10.2967/jnumed.115.156927
Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET
J. Yan (2015)
Prognostic factors in non - small
Brundage
10.21037/JTD.2016.08.25
Efficacy of lymph node dissection during robotic-assisted lobectomy for non-small cell lung cancer: retrospective review of 159 consecutive cases.
F. Velez-Cubian (2016)
10.1378/CHEST.122.3.1037
Prognostic factors in non-small cell lung cancer: a decade of progress.
M. Brundage (2002)
10.2967/jnumed.115.163469
Tumor Texture Analysis in PET: Where Do We Stand?
I. Buvat (2015)
10.1007/s11307-016-0940-2
Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation
F. V. van Velden (2016)
10.1016/S1470-2045(13)70334-6
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
M. Hellmann (2014)
10.2214/AJR.15.15864
Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges.
Usman Bashir (2016)
10.1073/pnas.0437788100
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
Meili Zhang (2003)
10.1097/RLU.0000000000000867
Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung Cancer
D. Kim (2015)
10.1002/mp.12309
Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall‐cell lung cancer patients treated with stereotactic body radiotherapy
Q. Li (2017)
10.2967/jnumed.113.133389
Visual Versus Quantitative Assessment of Intratumor 18F-FDG PET Uptake Heterogeneity: Prognostic Value in Non–Small Cell Lung Cancer
F. Tixier (2014)
10.1186/1471-2407-14-896
Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC
I. Apostolova (2014)
10.1016/j.radonc.2016.05.024
CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer.
E. Huynh (2016)
10.1259/bjr.20160665
Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures
R. Larue (2017)
10.21037/ATM.2016.09.09
Lymph node dissection after pulmonary resection for lung cancer: a mini review.
S. Korasidis (2016)
10.1016/j.chest.2016.10.010
The Eighth Edition Lung Cancer Stage Classification
F. Detterbeck (2017)
10.1016/j.ejca.2011.11.036
Radiomics: extracting more information from medical images using advanced feature analysis.
P. Lambin (2012)



This paper is referenced by
10.1007/s00066-019-01483-0
Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics
L. Cozzi (2019)
10.21037/tlcr-19-577
Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma.
D. Xie (2020)
10.1016/j.ejmp.2019.03.024
Early survival prediction in non-small cell lung cancer from PET/CT images using an intra-tumor partitioning method.
M. Astaraki (2019)
10.1007/s00259-018-3987-2
Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions
M. Kirienko (2018)
10.1007/s00330-020-07507-z
Is FDG-PET texture analysis related to intratumor biological heterogeneity in lung cancer?
M. Piñeiro-Fiel (2020)
10.1007/s00259-020-04684-3
18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients
Pan-li Li (2020)
10.1016/j.athoracsur.2020.01.010
Radiomics Signature Predicts the Recurrence-Free Survival in Stage I Non-Small-Cell Lung Cancer.
Tingting Wang (2020)
10.1155/2018/5076269
DCE-MRI Pharmacokinetic-Based Phenotyping of Invasive Ductal Carcinoma: A Radiomic Study for Prediction of Histological Outcomes
S. Monti (2018)
10.3390/cancers12051303
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology
S. Frega (2020)
10.1093/annonc/mdz108
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
S. Trebeschi (2019)
10.1080/14737140.2021.1852935
Radiomics features as predictive and prognostic biomarkers in NSCLC.
C. Bortolotto (2020)
10.1007/s00259-019-04372-x
Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics
M. Sollini (2019)
10.3389/fonc.2020.01042
Development and Validation of a Radiomics Nomogram Based on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Clinicopathological Factors to Predict the Survival Outcomes of Patients With Non-Small Cell Lung Cancer
Bin Yang (2020)
10.1002/cam4.2711
Radiomics based on 18F‐FDG PET/CT could differentiate breast carcinoma from breast lymphoma using machine‐learning approach: A preliminary study
Xuejin Ou (2019)
10.1016/j.remn.2019.10.003
Interdisciplinaridad: un requerimiento esencial para la traslación de investigación en radiómica a la práctica clínica
M. Sollini (2020)
10.1097/MD.0000000000014876
Intratumoral heterogeneity as measured using the tumor-stroma ratio and PET texture analyses in females with lung adenocarcinomas differs from that of males with lung adenocarcinomas or squamous cell carcinomas
Y. W. Koh (2019)
10.1016/j.mednuc.2019.09.001
Analyse texturale en TEP au FDG des cancers pulmonaires non à petites cellules de stade localement avancé : valeur pronostique de l’entropie
A. Moubtakir (2020)
10.3389/fphy.2018.00051
Personalizing Medicine Through Hybrid Imaging and Medical Big Data Analysis
L. Papp (2018)
10.1016/j.acra.2019.04.016
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Mengmeng Jiang (2019)
10.1016/j.acra.2019.05.019
CT Radiomics Signature of Tumor and Peritumoral Lung Parenchyma to Predict Nonsmall Cell Lung Cancer Postsurgical Recurrence Risk.
Tugba Akinci D'Antonoli (2019)
10.1186/s41824-020-00078-8
Methodological framework for radiomics applications in Hodgkin’s lymphoma
M. Sollini (2020)
10.1016/j.crad.2019.02.008
Pre-treatment 18F-FDG PET-based radiomics predict survival in resected non-small cell lung cancer.
H. Ahn (2019)
10.21037/TLCR.2020.04.17
Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features.
Q. Liu (2020)
10.1371/journal.pone.0225242
Metastasis risk prediction model in osteosarcoma using metabolic imaging phenotypes: A multivariable radiomics model
Heesoon Sheen (2019)
10.1007/s00259-020-04747-5
Additional value of metabolic parameters to PET/CT-based radiomics nomogram in predicting lymphovascular invasion and outcome in lung adenocarcinoma
P. Nie (2020)
10.1007/s11307-018-01304-3
Radiomics Analysis of PET and CT Components of PET/CT Imaging Integrated with Clinical Parameters: Application to Prognosis for Nasopharyngeal Carcinoma
Wenbing Lv (2019)
10.1007/s11307-020-01552-2
Contrast-Enhanced CT-based Textural Parameters as Potential Prognostic Factors of Survival for Colorectal Cancer Patients Receiving Targeted Therapy
Y. Zhao (2020)
10.1055/A-0838-8135
Big Imaging Data: Klinische Bildanalyse mit Radiomics und Deep Learning
Aydin Demircioglu (2019)
10.23736/S1824-4785.19.03192-3
CT radiomics and PET radiomics: ready for clinical implementation?
M. Bogowicz (2019)
10.1111/1759-7714.13336
Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm
Chien-Sheng Huang (2020)
10.1371/journal.pone.0210758
Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma
L. Cozzi (2019)
10.1007/s00066-019-01542-6
A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer.
D. Franceschini (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar